Teva Pharmaceutical Industries Limited (ADR)
General ticker "TEVA" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $20.5B (TTM average)
Teva Pharmaceutical Industries Limited (ADR) follows the US Stock Market performance with the rate: 56.2%.
Estimated limits based on current volatility of 1.9%: low 31.79$, high 33.01$
Factors to consider:
- Total employees count: 36830 (-2.7%) as of 2024
- US accounted for 38.2% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Drug development risks, Supply chain disruptions, Cybersecurity threats, Economic downturns and volatility
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [22.35$, 35.38$]
- 2026-12-31 to 2027-12-31 estimated range: [20.84$, 33.81$]
Financial Metrics affecting the TEVA estimates:
- Positive: with PPE of 10.7 at the end of fiscal year the price was neutral
- Positive: 7.67 < Operating profit margin, % of 12.50
- Positive: Inventory ratio change, % of 0.19 <= 0.80
- Positive: Investing cash flow per share per price, % of 2.06 > -0.63
- Positive: Interest expense per share per price, % of 2.56 <= 3.28
- Positive: 19.40 < Shareholder equity ratio, % of 19.41 <= 42.68
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 3.36
- Negative: negative Industry operating income (median)
Short-term TEVA quotes
Long-term TEVA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $15,895.00MM | $16,558.00MM | $17,257.00MM |
| Operating Expenses | $15,462.00MM | $16,861.00MM | $15,100.00MM |
| Operating Income | $433.00MM | $-303.00MM | $2,157.00MM |
| Non-Operating Income | $-1,057.00MM | $-981.00MM | $-919.00MM |
| Interest Expense | $0.00MM | $0.00MM | $916.00MM |
| R&D Expense | $953.00MM | $998.00MM | $1,013.00MM |
| Income(Loss) | $-624.00MM | $-1,284.00MM | $1,238.00MM |
| Taxes | $-7.00MM | $676.00MM | $-180.00MM |
| Other Income(Loss) | $2.00MM | $1.00MM | $0.00MM |
| Profit(Loss)* | $-559.00MM | $-1,639.00MM | $1,410.00MM |
| Stockholders Equity | $7,506.00MM | $5,373.00MM | $7,909.88MM |
| Inventory | $4,021.00MM | $3,007.00MM | $3,178.95MM |
| Assets | $43,479.00MM | $39,326.00MM | $40,747.37MM |
| Operating Cash Flow | $1,368.00MM | $1,247.00MM | $1,649.00MM |
| Capital expenditure | $526.00MM | $498.00MM | $501.00MM |
| Investing Cash Flow | $968.00MM | $792.00MM | $737.00MM |
| Financing Cash Flow | $-1,913.00MM | $-1,791.00MM | $-2,151.00MM |
| Earnings Per Share** | $-0.50 | $-1.45 | $1.23 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.